New research suggests that individuals who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who stop conventional lifestyle regimens.
Research printed in a leading health publication shows that while overweight people can lose about a fifth of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Users buying such drugs should be cognizant of the potential of quick rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass in about one and a half years.
Comparing Approaches
The research, which looked at dozens of studies involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
The team point out that individuals who lose weight through lifestyle changes alone generally have a slower creep back—approximately 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Experts propose the mechanism of the injections accounts for the amplified rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication means hunger is uncontrolled, making overeating much more probable."
A Lifelong Condition?
Health authorities recommend the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts argue that, given the likelihood of weight regain, the therapy should be considered ongoing.
This opinion is supported by drug manufacturers, who say that the results "emphasize the long-term character of excess weight," similar to managing conditions like diabetes.
Patient Experiences
Individuals who have come off the medication report a powerful return of hunger.
"It felt as if something activating and you become extremely hungry," said a patient.
This challenge is worsened if users have not established permanent dietary or behavioural modifications during treatment.
Widespread Interest
Recent estimates suggest that millions of adults in the UK have used these injections in the last 12 months, with demand being substantial.
- Use is more common among females than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and long-term success hinges on combined behavioural changes.
